MedTrace Logo

The DENOCHARCOT Trial

NCT04547348 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-08-07

No results posted yet for this study

Summary

The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia® on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.

Conditions

Interventions

DRUG

Denosumab Injection

Injections made subcutaneously per standard description

Sponsors & Collaborators

  • Ole Lander Svendsen

    lead OTHER

Principal Investigators

  • Ole Lander Svendsen, MD · Region Hovedstadens Apotek

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2025-10-01
Completion
2026-10-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04547348 on ClinicalTrials.gov